Dow Jones
39.806,77 -196,82 (-0,49%) Nasdaq
16.794,88 +108,91 (+0,65%) Nikkei 225
38.946,93 -122,75 (-0,31%) EUR/USD
1,0861 0,0000 (-0,00%) Bitcoin EUR
65.570,41 +4.158,84 (+6,77%) CMC Crypto 200
1.530,91 +42,37 (+2,85%)
CRNX May 2024 50.000 call
| Chiusura precedente | 1,8700 |
| Aperto | 1,3500 |
| Denaro | 0,5500 |
| Lettera | 3,6000 |
| Prezzo d'esercizio | 50,00 |
| Scadenza | 2024-05-17 |
| Min-Max giorno | 1,3500 - 3,6000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 285 |
GlobeNewswireCrinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on October 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 619,100 shares of its common stock to eleven new non-ex
- GlobeNewswire
Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023
SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Cantor Global Healthcare Conference, which is being held in New York City on September 26-28, 2023. Details of the fireside chat are as follows: Date: Tuesday, September 26, 2023Time: 1:00 p.m. Eastern Time The live and archived webcast will be accessible on the Events & Presentations page in the
- GlobeNewswire
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today the pricing of an upsized underwritten public offering of 11,441,648 shares of its common stock at a price to the public of $30.59 per share. All of the shares to be sold in the offering are to be sold by Crinetics.
